Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Hendrickx

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Plos Pathogens|April 24, 2024
Long-term hematopoietic stem cells trigger quiescence in Leishmania parasitesLaura Dirkx, Sara I Van Acker, Yasmine Nicolaes, et al.
Plos One|April 29, 2016
Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular AmastigotesAnnelies Mondelaers, Maria P Sanchez-Cañete, Sarah Hendrickx, et al.
Natural Product Research|February 10, 2018
Report of <i>in vitro</i> antileishmanial properties of Iberian macroalgaeCarolina Bruno de Sousa, João Henrique G Lago, Jorge Macridachis, et al.
The Journal of Antimicrobial Chemotherapy|May 5, 2026
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 1: setting the stageSarah Hendrickx, Kayhan Ilbeigi, Eli S J Thoré, et al.
The Journal of Antimicrobial Chemotherapy|March 31, 2026
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 2: from molecule to confirmed hitSarah Hendrickx, Kayhan Ilbeigi, Eli S J Thoré, et al.
The Journal of Antimicrobial Chemotherapy|May 11, 2026
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 3: from lead towards a drug development candidateSarah Hendrickx, Kayhan Ilbeigi, Eli S J Thoré, et al.
Nature Communications|February 27, 2024
Q586B2 is a crucial virulence factor during the early stages of Trypanosoma brucei infection that is conserved amongst trypanosomatidsBenoit Stijlemans, Patrick De Baetselier, Inge Van Molle, et al.
Science Translational Medicine|December 13, 2023
DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc<sub>1</sub>Stéphanie Braillard, Martine Keenan, Karen J Breese, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Plos Pathogens|April 24, 2024
Long-term hematopoietic stem cells trigger quiescence in Leishmania parasitesLaura Dirkx, Sara I Van Acker, Yasmine Nicolaes, et al.
Plos One|April 29, 2016
Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular AmastigotesAnnelies Mondelaers, Maria P Sanchez-Cañete, Sarah Hendrickx, et al.
Natural Product Research|February 10, 2018
Report of <i>in vitro</i> antileishmanial properties of Iberian macroalgaeCarolina Bruno de Sousa, João Henrique G Lago, Jorge Macridachis, et al.
The Journal of Antimicrobial Chemotherapy|May 5, 2026
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 1: setting the stageSarah Hendrickx, Kayhan Ilbeigi, Eli S J Thoré, et al.
The Journal of Antimicrobial Chemotherapy|March 31, 2026
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 2: from molecule to confirmed hitSarah Hendrickx, Kayhan Ilbeigi, Eli S J Thoré, et al.
The Journal of Antimicrobial Chemotherapy|May 11, 2026
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 3: from lead towards a drug development candidateSarah Hendrickx, Kayhan Ilbeigi, Eli S J Thoré, et al.
Nature Communications|February 27, 2024
Q586B2 is a crucial virulence factor during the early stages of Trypanosoma brucei infection that is conserved amongst trypanosomatidsBenoit Stijlemans, Patrick De Baetselier, Inge Van Molle, et al.
Science Translational Medicine|December 13, 2023
DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc<sub>1</sub>Stéphanie Braillard, Martine Keenan, Karen J Breese, et al.
Pageof 5